Joel Kremer
Overview
Explore the profile of Joel Kremer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
59
Citations
3682
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Reed G, Gerber R, Shan Y, Takiya L, Dandreo K, Gruben D, et al.
Rheumatol Ther
. 2019 Nov;
PMID: 31707603
Introduction: No published studies exist comparing the effectiveness of tofacitinib with other advanced therapies for the treatment of rheumatoid arthritis (RA) in real-world clinical practice. Here, we report differences in...
12.
Peterfy C, Kremer J, Rigby W, Singer N, Birchwood C, Gill D, et al.
J Rheumatol
. 2019 Jun;
47(3):325-332.
PMID: 31154414
Objective: To assess differences in joint damage and inflammation using magnetic resonance imaging (MRI) between patients with rheumatoid arthritis (RA) who achieved low disease activity with tocilizumab (TCZ) + methotrexate...
13.
van der Heijde D, Strand V, Tanaka Y, Keystone E, Kremer J, Zerbini C, et al.
Arthritis Rheumatol
. 2019 Jan;
71(6):878-891.
PMID: 30666826
Objective: Tofacitinib is an oral JAK inhibitor for the treatment of rheumatoid arthritis (RA). The phase III, 24-month, placebo-controlled Oral Rheumatoid Arthritis (ORAL) Scan trial was undertaken to evaluate the...
14.
Lee Y, Kremer J, Guan H, Greenberg J, Solomon D
Arthritis Rheumatol
. 2018 Nov;
71(5):670-677.
PMID: 30474933
Objective: The opioid epidemic is a major public health concern. However, little is known about opioid use among rheumatoid arthritis (RA) patients. We undertook this study to examine trends in...
15.
Li Z, Liu Y, Xu H, Chen Z, Bao C, Gu J, et al.
Chin Med J (Engl)
. 2018 Nov;
131(22):2683-2692.
PMID: 30425195
Background: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). This study assessed the efficacy and safety of tofacitinib in Chinese patients with RA enrolled...
16.
ODell J, Cohen S, Thorne J, Kremer J
Open Access Rheumatol
. 2018 Jul;
10:97-101.
PMID: 30013407
Purpose: The objective of this study was to assess the treatment for patients with rheumatoid arthritis (RA) in the USA. Patients And Methods: This study entailed analysis of claims data...
17.
Strand V, Miller P, Williams S, Saunders K, Grant S, Kremer J
Rheumatol Ther
. 2017 Aug;
4(2):489-502.
PMID: 28831751
Introduction: Despite the availability of multiple effective therapies, discontinuation/switching of treatment is common for many patients with rheumatoid arthritis (RA). This study was designed to examine initiation of biologic disease-modifying...
18.
Cappelli L, Palmer J, Kremer J, Bingham 3rd C
Semin Arthritis Rheum
. 2017 May;
47(2):165-169.
PMID: 28477897
Objective: Autoantibodies can be useful in predicting response to certain treatments in rheumatoid arthritis (RA). We aimed to evaluate initial response to tocilizumab (TCZ) by change in physician and patient-reported...
19.
Burmester G, McInnes I, Kremer J, Miranda P, Korkosz M, Vencovsky J, et al.
Ann Rheum Dis
. 2017 Feb;
76(6):1020-1030.
PMID: 28213566
Objectives: Despite the therapeutic value of current rheumatoid arthritis (RA) treatments, agents with alternative modes of action are required. Mavrilimumab, a fully human monoclonal antibody targeting the granulocyte-macrophage colony-stimulating factor...
20.
Sieberts S, Zhu F, Garcia-Garcia J, Stahl E, Pratap A, Pandey G, et al.
Nat Commun
. 2016 Oct;
7:13205.
PMID: 27721464
No abstract available.